Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone Sodium Phosphate in Acute Disabling Non-Large Vessel Occlusion Ischemic Stroke
ChiCTR2600123580Phase 3Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in brain infarction (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: All-cause mortality at 90 days, Symptomatic intracranial hemorrhage within 48 hours and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
dexamethasone
03
Conditions
brain infarction
Beyond the preview
Go deeper on ChiCTR2600123580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123580.